Bioam Gestion

Bioam Gestion invests across venture and growth equity stages within the life sciences sector. The firm typically enters at early clinical or late pre-clinical phases for biotech assets, and at commercialization-stage for medical device and digital health companies, as indicated by its public portfolio holdings such as Sensorion and Theraclion.

The firm concentrates on three sub-verticals: biotechnology, including gene and cell therapies; medical technology, such as non-invasive surgical devices; and digital health. Its historical funds have also included mandates for rare diseases and agricultural biology, per the firm's official investment descriptions.

Bioam is one of a small number of dedicated life sciences venture capital managers headquartered in Paris, distinct from larger French multi-asset managers that run health-sector sleeves within diversified funds. It operates independently and is not a subsidiary of a banking group or insurance conglomerate.

Olivier de Fougeroux, the founder and president, leads the investment team. Public records and fund documentation list him as the central decision-maker since the firm's inception in 1998, though the full composition of the investment committee is not publicly detailed.

Bioam Gestion invests directly into private European life sciences companies. There is no public record of the firm operating as a fund-of-funds or making LP commitments to other venture capital managers.